AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 242 min read$COO

CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal?

CooperCompanies (COO) reported 1% revenue growth and 4% EPS increase in Q3. The company completed a strategic review, deciding to retain CooperSurgical and expand its share buyback program to $3 billion. Operational improvements and cost-cutting measures are planned. Institutional interest slightly increased, with BlackRock as the largest shareholder.

Original reporting
insidermonkey.com
Published Sep 24, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$COOBullishMed
01

Why it matters

The retention of CooperSurgical and larger buyback suggest management confidence, but modest Q3 growth highlights ongoing challenges.

02

Market read

The announcement provides fresh corporate action news that could influence COO's short-term price dynamics.

03

What to watch

Potential cash constraints if future acquisitions are pursued; macro headwinds affecting elective procedures.

Relevance 7/10Novelty 7/10Timing: as of Sep 24

Background

Cooper Companies completed its strategic review, retained CooperSurgical, and announced an expanded buyback program.

Company-level read

Ticker impact

$COOBullishHigh confidence
Context

Board expanded the share repurchase program from $2B to $3B, signaling confidence and potential price support for COO.

Expected impact

Modest upside pressure as the market absorbs the increased buyback capacity.

Evidence & confidence

Buyback expansions are typically viewed as a bullish signal, especially when the company retains a strategic unit.

Market effects

Sector

The medical device sector may see a modest uplift as a peer demonstrates confidence through buybacks.

Regional

U.S. equities could receive a slight positive bias from the announcement.

Global

Limited to investors tracking U.S. healthcare stocks.

Counterpoint

What could challenge this read

The buyback may mask underlying growth challenges in CooperVision and could be a short-term price prop.

Key entities

  • Company
    The Cooper Companies Inc.

    Medical device and fertility solutions provider (ticker COO).

Read at source← All news

Related articles

SEP 21
$COOMedAI 8/10

A Failed Auction and a 15% Drop: Is Cooper Companies (COO) a Value Trap or a Bargain?

Cooper Companies (COO) ended its 9-month effort to sell CooperSurgical after bids undervalued the business, according to management. The stock dropped 15% to a 52-week low near $51 after a Q3 miss and cut outlook. The company's core contact lens business, CooperVision, posted flat organic revenue growth, contributing to the guidance cut. Management authorized a $1B share repurchase program, while Bank of America questioned the valuation. COO reported record Q3 free cash flow of $273M.

insidermonkey.com2 min
SEP 14
$COOMedAI 8/10

The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand

The Cooper Companies (COO) lowered its fiscal 2026 profit and revenue forecasts due to weaker-than-expected contact lens demand, with adjusted EPS now expected at $4.51–$4.55 and revenue at $4.23–$4.25 billion. Q3 revenue was $1.07 billion, missing estimates, though adjusted EPS beat at $1.15. The company cited U.S. channel inventory reductions as a key factor and decided to retain CooperSurgical.

finance.yahoo.com3 min
SEP 11
$COOMedAI 8/10

Cooper Companies (COO) Bets on Fertility Growth Despite Weakness in CooperVision

Cooper Companies (COO) reported Q3 FY2026 revenue of $1.066B, up 1%, and adjusted EPS of $1.15, up 4%. The company spent $339.1M on share buybacks and has $1.5B remaining in repurchase capacity. Fertility segment growth and strong cash flow offset weakness in CooperVision, which saw flat organic growth and revenue declines in Americas and Asia Pacific. Gross margin improved to 67% on a GAAP basis, while adjusted operating margin rose 30 basis points to 26%.

yahoo.com2 min
SEP 11
$COOMed

Why Cooper, Freeport-McMoRan, and Baker Hughes Plunged

Cooper Companies (COO) fell 14.67% after reporting Q3 revenue of $1.07B and Q4 guidance below estimates. Freeport-McMoRan (FCX) dropped 6.59% due to White House uncertainty on copper tariffs. Baker Hughes (BKR) declined 6.66% despite raising its full-year revenue guidance to $28.5B-$30.3B.

baystreet.ca2 min
SEP 11
$COOMedAI 8/10

COO Q2 Deep Dive: Inventory Actions and Strategic Review Shape Guidance

CooperCompanies reported Q2 revenue of $1.07B (flat YoY, 2.9% miss) and adjusted EPS of $1.15 (2.7% beat). Full-year guidance was lowered to $4.24B revenue and $4.53 EPS. The company reduced U.S. inventory and retained CooperSurgical after a strategic review. Management plans to invest in sales and R&D, aiming for future growth and improved margins.

yahoo.com2 min